24/7 Market News Snapshot 14 Aug 2024 – Unicycive Therapeutics, Inc. Common Stock (NASDAQ: UNCY)

August 14, 2024 6:23

Press Release

DENVER, Colo., 14 August, 2024 (247marketnews.com) – (Nasdaq:UNCY) are discussed in this article.
Unicycive Therapeutics, Inc. (UNCY) demonstrated strong market performance today, opening at $0.25 and achieving a 27.97% increase to $0.30, compared to the previous session’s close at $0.236. This notable price surge, accompanied by a significant trading volume of 5.1 million shares, suggests robust investor interest and positive market sentiment, hinting at potential bullish momentum for the company. While these technical indicators show promise, further analysis is recommended for investors considering UNCY.

In a concurrent development, Unicycive Therapeutics has announced a pivotal milestone in its mission to transform kidney disease treatment. The company plans to submit a New Drug Application (NDA) for its leading therapeutic candidate, OLC, by the end of August 2024. This announcement aligns with the release of Unicycive’s financial results for the quarter ending June 30, 2024, reflecting its strategic and financial commitment to advancing renal healthcare solutions.

Dr. Shalabh Gupta, CEO of Unicycive Therapeutics, expressed his enthusiasm for this crucial progression. “We are thrilled to be on track with our submission timetable for OLC. This marks a critical step forward in our efforts to provide innovative solutions for patients suffering from kidney diseases, a community that has long been in need of more effective therapeutic options.”

OLC has shown significant promise in addressing unmet medical needs in renal care, with the NDA submission representing the culmination of extensive research and development efforts. The company’s dedication to scientific excellence and patient-centered care is evident in its strategic initiatives and operational focus.

Despite economic challenges, Unicycive’s financial results indicate strong fiscal management and a robust research and development pipeline. The company continues to progress towards its objectives, underpinned by a clear vision and commitment to innovation.

This milestone is not only a leap forward for Unicycive but also holds the potential to transform the treatment paradigm for kidney disease, offering hope to patients worldwide. Unicycive Therapeutics remains at the forefront of biotechnology advancements, steadfast in its mission to enhance patient outcomes through pioneering therapies.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.